angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
By converting 1, 2-diacylglycerol into phosphatidylcholine Stimulating the synthesis of SAMe, which aids in membrane stabilization and reduces levels of arachidonic acid. This is especially important after an ischemia when arachidonic acid levels are elevated.
== Promotional sponsorship == Major League Soccer team Real Salt Lake announced on October 29, 2013, that it had partnered with LifeVantage for a long-term, multimillion-dollar jersey-front sponsorship. The partnership was set to formally go into effect on January 1, 2014, with the LifeVantage logo appearing on the Real Salt Lake jersey starting in the next season. In July 2015, Real Salt Lake owner Dell Loy Hansen was reported by the U.S. Securities and Exchange Commission to have bought a 5.1 percent ownership stake in LifeVantage.
== Career == Yates started working out properly in 1983 at Martin's Gym in the Temple Row area of Birmingham. During this time, he won the 1984 Mr. Birmingham and became the British Heavyweight Bodybuilding Champion for the first time in 1986. His professional record consists of 15 major contest wins and two second-place finishes, and he won every contest he entered from 1992 until his retirement in 1997. His career ended in large part due to injuries such as torn biceps and triceps, the latter occurring three weeks before his final contest at the 1997 Mr. Olympia, which he nevertheless won; his victory generated controversy, with many critics and fans alike believing the runner-up Nasser El Sonbaty deserved to win. He is one of only four men to retire as a reigning Mr. Olympia. Peter McGough gave Yates the nickname "The Shadow" for his tendency to unexpectedly appear at major bodybuilding contests and win, having neither confirmed nor denied whether he would compete beforehand, and for staying out of the public eye between contests. He is considered to be the first of the "mass monsters" in bodybuilding; he combined his enormous muscle mass along with peak conditioning, quoted as being "granite hardness". He believes his career-ending injuries were due to his habit of maintaining an extreme level of training intensity all year long, even when approaching contests and while cutting weight.
Proposed mitigation strategies include factoring potential environmental costs prior to model development or data collection, increasing efficiency of data centers to reduce electricity/energy usage, building more efficient machine learning models, minimizing the number of times that models need to be retrained, developing a government-directed framework for auditing the environmental impact of these models, regulating for transparency of these models, regulating their energy and water usage, encouraging researchers to publish data on their models' carbon footprint, and increasing the number of subject matter experts who understand both machine learning and climate science.
== Further reading == "Plates vs. Plumes: A Geological Controversy". Wiley-Blackwell. October 2010. Boschi, L.; Becker, T.W.; Steinberger, B. (2007). "Mantle plumes: Dynamic models and seismic images" (PDF). Geochemistry, Geophysics, Geosystems. 8 (Q10006): Q10006. Bibcode:2007GGG.....810006B. doi:10.1029/2007GC001733. ISSN 1525-2027. Clouard, Valérie; Gerbault, Muriel (2007). "Break-up spots: Could the Pacific open as a consequence of plate kinematics?" (PDF). Earth and Planetary Science Letters. 265 (1–2): 195. Bibcode:2008E&PSL.265..195C. doi:10.1016/j.epsl.2007.10.013. "Towards A Better Understanding Of Hot Spot Volcanism". ScienceDaily. 4 February 2008.
Sources: en.wikipedia.org
=== Pharmacokinetics === Chloral hydrate is metabolized to both 2,2,2-trichloroethanol (TCE) and trichloroacetic acid (TCA) by alcohol dehydrogenase. TCE is further converted to its glucoronide. Dichloroacetic acid (DCA) has been detected as a metabolite in children, but how it gets made is unknown. TCE glucoronide, TCA, and a very small amount of free TCE are excreted in urine in male human adults. This study did not detect significant amounts of DCA; the authors noted that DCA can form during inappropriate sample preparation. Both TCA and DCA cause liver tumors in mice. TCA is cleared by the kidneys at a rate slower than the expected filtration rate, suggesting that efficient reabsorption of filtered-out TCA happens.
The F1 fraction derives its name from the term "Fraction 1" and FO (written as a subscript letter "o", not "zero") derives its name from being the binding fraction for oligomycin, a type of naturally derived antibiotic that is able to inhibit the FO unit of ATP synthase. These functional regions consist of different protein subunits — refer to tables. This enzyme is used in synthesis of ATP through aerobic respiration. Located within the thylakoid membrane and the inner mitochondrial membrane, ATP synthase consists of two regions FO and F1. FO causes rotation of F1 and is made of c-ring and subunits a, two b, F6. F1 is made of α, β, γ, and δ subunits. F1 has a water-soluble part that can hydrolyze ATP. FO on the other hand has mainly hydrophobic regions. FO F1 creates a pathway for protons movement across the membrane.
In this process, rare-earth ions are adsorbed onto suitable ion-exchange resin by exchange with hydrogen, ammonium or cupric ions present in the resin. Lutetium salts are then selectively washed out by suitable complexing agent. Lutetium metal is then obtained by reduction of anhydrous LuCl3 or LuF3 by either an alkali metal or alkaline earth metal.
Extended insulin zinc insulin (Ultralente) Insulin glargine (Lantus) Insulin detemir (Levemir) Insulin degludec (Tresiba) Insulin degludec is sometimes classed separately as an "ultra-long" acting insulin due to its duration of action of about 42 hours, compared with 24 hours for most other long-acting insulin preparations. As a systematic review of studies comparing insulin detemir, insulin glargine, insulin degludec and NPH insulin did not show any clear benefits or serious adverse effects for any particular form of insulin for nocturnal hypoglycemia, severe hypoglycemia, glycated hemoglobin A1c, non-fatal myocardial infarction/stroke, health-related quality of life or all-cause mortality. The same review did not find any differences in effects of using these insulin analogues between adults and children. Most oral anti-diabetic agents are contraindicated in pregnancy, in which case insulin is preferred. Insulin is not administered by other routes, although this has been studied. An inhaled form was briefly licensed but was subsequently withdrawn.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.